| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 60 | 2021 | 4823 | 4.020 |
Why?
|
| Neoplasms, Glandular and Epithelial | 9 | 2010 | 484 | 1.650 |
Why?
|
| Peritoneal Neoplasms | 7 | 2012 | 663 | 1.000 |
Why?
|
| Genes, BRCA1 | 5 | 2011 | 780 | 0.980 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2019 | 11472 | 0.930 |
Why?
|
| Periodicals as Topic | 5 | 2020 | 1431 | 0.910 |
Why?
|
| Fallopian Tube Neoplasms | 5 | 2012 | 324 | 0.880 |
Why?
|
| Platinum | 3 | 2019 | 232 | 0.810 |
Why?
|
| Paclitaxel | 12 | 2011 | 1707 | 0.770 |
Why?
|
| Evaluation Studies as Topic | 2 | 2013 | 1676 | 0.750 |
Why?
|
| Colony-Stimulating Factors | 16 | 1991 | 216 | 0.670 |
Why?
|
| Genes, BRCA2 | 3 | 2011 | 617 | 0.660 |
Why?
|
| Editorial Policies | 2 | 2020 | 451 | 0.640 |
Why?
|
| Genital Neoplasms, Female | 2 | 2019 | 516 | 0.630 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2010 | 319 | 0.620 |
Why?
|
| Medical Oncology | 6 | 2019 | 2235 | 0.580 |
Why?
|
| Organoplatinum Compounds | 6 | 2011 | 408 | 0.580 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 7901 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2019 | 9185 | 0.490 |
Why?
|
| Peritoneum | 4 | 2011 | 226 | 0.470 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2004 | 623 | 0.470 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2007 | 450 | 0.460 |
Why?
|
| Taxoids | 4 | 2004 | 665 | 0.450 |
Why?
|
| Neoplasms | 11 | 2020 | 21596 | 0.440 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2019 | 5163 | 0.440 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 13655 | 0.420 |
Why?
|
| Carboplatin | 7 | 2023 | 799 | 0.400 |
Why?
|
| Information Dissemination | 1 | 2019 | 1100 | 0.390 |
Why?
|
| Carcinoma | 6 | 2011 | 2374 | 0.370 |
Why?
|
| Growth Substances | 10 | 1990 | 783 | 0.370 |
Why?
|
| Gene Expression Profiling | 6 | 2011 | 9410 | 0.350 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2001 | 4553 | 0.350 |
Why?
|
| Neoplasm Proteins | 6 | 2011 | 3691 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 1999 | 1434 | 0.350 |
Why?
|
| Informed Consent | 2 | 2007 | 991 | 0.340 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2001 | 59 | 0.340 |
Why?
|
| Topotecan | 2 | 2007 | 138 | 0.330 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2011 | 364 | 0.320 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2009 | 627 | 0.320 |
Why?
|
| Endometrial Neoplasms | 3 | 2019 | 1351 | 0.310 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2012 | 2038 | 0.290 |
Why?
|
| Tumor Cells, Cultured | 19 | 2000 | 6313 | 0.290 |
Why?
|
| Monocytes | 13 | 1992 | 2593 | 0.280 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 16 | 2000 | 902 | 0.280 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2011 | 3920 | 0.270 |
Why?
|
| Female | 72 | 2021 | 379592 | 0.270 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 252 | 0.270 |
Why?
|
| Humans | 112 | 2023 | 742088 | 0.260 |
Why?
|
| Microarray Analysis | 1 | 2008 | 766 | 0.260 |
Why?
|
| Treatment Outcome | 14 | 2019 | 62966 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 14 | 2019 | 9274 | 0.250 |
Why?
|
| Apoptosis | 5 | 1999 | 9715 | 0.250 |
Why?
|
| Granulocytes | 7 | 1988 | 546 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2011 | 8425 | 0.250 |
Why?
|
| Drug Administration Schedule | 9 | 2019 | 4929 | 0.250 |
Why?
|
| Cisplatin | 4 | 2011 | 1637 | 0.240 |
Why?
|
| Receptors, Lymphocyte Homing | 2 | 1995 | 143 | 0.240 |
Why?
|
| Deoxycytidine | 2 | 2010 | 824 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2011 | 2906 | 0.230 |
Why?
|
| Publishing | 1 | 2011 | 833 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 12 | 1992 | 3381 | 0.230 |
Why?
|
| Germ-Line Mutation | 3 | 2019 | 1786 | 0.220 |
Why?
|
| Mullerian Ducts | 1 | 2003 | 198 | 0.210 |
Why?
|
| Granulosa Cell Tumor | 1 | 2003 | 70 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3130 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3236 | 0.200 |
Why?
|
| Patient Advocacy | 1 | 2004 | 353 | 0.200 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5304 | 0.200 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1993 | 689 | 0.200 |
Why?
|
| Leukemia, Myeloid | 5 | 1991 | 705 | 0.200 |
Why?
|
| Oncogenes | 3 | 2019 | 1263 | 0.200 |
Why?
|
| Gynecology | 1 | 2007 | 509 | 0.200 |
Why?
|
| Endpoint Determination | 1 | 2004 | 600 | 0.190 |
Why?
|
| Cell Adhesion | 7 | 1999 | 3139 | 0.190 |
Why?
|
| Cytarabine | 3 | 1993 | 684 | 0.190 |
Why?
|
| Prognosis | 13 | 2020 | 29010 | 0.190 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2001 | 150 | 0.180 |
Why?
|
| Receptors, Cell Surface | 5 | 1995 | 2867 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2004 | 839 | 0.180 |
Why?
|
| bcl-2-Associated X Protein | 5 | 1999 | 295 | 0.180 |
Why?
|
| Combined Modality Therapy | 6 | 2019 | 8621 | 0.180 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2011 | 221 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 17400 | 0.170 |
Why?
|
| Glycoproteins | 3 | 2003 | 2260 | 0.170 |
Why?
|
| Dermatomyositis | 1 | 2001 | 223 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 3 | 2010 | 891 | 0.170 |
Why?
|
| Infusions, Parenteral | 3 | 2011 | 415 | 0.150 |
Why?
|
| Research Design | 3 | 2009 | 5979 | 0.140 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 1986 | 1470 | 0.140 |
Why?
|
| Epithelium | 6 | 1999 | 1680 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 1997 | 2948 | 0.140 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 424 | 0.140 |
Why?
|
| Integrins | 3 | 1995 | 845 | 0.140 |
Why?
|
| Phthalazines | 1 | 2018 | 361 | 0.140 |
Why?
|
| Receptors, Cytoadhesin | 1 | 1995 | 8 | 0.140 |
Why?
|
| Tumor Stem Cell Assay | 3 | 1991 | 118 | 0.130 |
Why?
|
| Neoplasm Staging | 8 | 2011 | 11001 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 4 | 1994 | 1599 | 0.130 |
Why?
|
| Biopsy | 1 | 2007 | 6756 | 0.130 |
Why?
|
| Disease-Free Survival | 5 | 2010 | 6891 | 0.130 |
Why?
|
| Drug Interactions | 2 | 2010 | 1458 | 0.120 |
Why?
|
| Mutation | 4 | 2018 | 29717 | 0.120 |
Why?
|
| Survival Analysis | 8 | 2019 | 10248 | 0.120 |
Why?
|
| Rectum | 1 | 2019 | 903 | 0.120 |
Why?
|
| Platinum Compounds | 2 | 2010 | 96 | 0.120 |
Why?
|
| Biological Products | 1 | 2003 | 856 | 0.120 |
Why?
|
| Carrier Proteins | 3 | 1998 | 5019 | 0.120 |
Why?
|
| Oligopeptides | 3 | 1995 | 1176 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 3611 | 0.120 |
Why?
|
| Indium Radioisotopes | 1 | 1993 | 118 | 0.120 |
Why?
|
| Middle Aged | 26 | 2019 | 213127 | 0.120 |
Why?
|
| RNA, Neoplasm | 2 | 2008 | 768 | 0.120 |
Why?
|
| Pentetic Acid | 1 | 1993 | 213 | 0.120 |
Why?
|
| Growth Inhibitors | 2 | 2003 | 385 | 0.110 |
Why?
|
| Hysterectomy | 1 | 2019 | 927 | 0.110 |
Why?
|
| Interleukin-3 | 5 | 1991 | 441 | 0.110 |
Why?
|
| Signal Transduction | 6 | 2011 | 23387 | 0.110 |
Why?
|
| DNA, Neoplasm | 3 | 2011 | 1758 | 0.100 |
Why?
|
| Patient Selection | 1 | 2004 | 4214 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 9941 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 1991 | 3497 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2004 | 3471 | 0.100 |
Why?
|
| Ovary | 3 | 2004 | 981 | 0.100 |
Why?
|
| Interferon-gamma | 7 | 1989 | 3199 | 0.100 |
Why?
|
| Erythroid Precursor Cells | 1 | 1992 | 218 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 1477 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 1999 | 1983 | 0.100 |
Why?
|
| Injections, Intraperitoneal | 2 | 2003 | 424 | 0.100 |
Why?
|
| Exonucleases | 1 | 2010 | 47 | 0.090 |
Why?
|
| Aged | 20 | 2019 | 162944 | 0.090 |
Why?
|
| Ethics, Medical | 2 | 2007 | 791 | 0.090 |
Why?
|
| Bone Marrow | 6 | 1993 | 2941 | 0.090 |
Why?
|
| Transfection | 5 | 1998 | 5892 | 0.090 |
Why?
|
| Interleukin-1 | 3 | 1989 | 1262 | 0.090 |
Why?
|
| Dioxoles | 1 | 2010 | 104 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2699 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6534 | 0.090 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2010 | 91 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2009 | 10943 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 1993 | 2027 | 0.090 |
Why?
|
| Bone Marrow Cells | 4 | 1992 | 2513 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 3 | 2005 | 1799 | 0.090 |
Why?
|
| Immunohistochemistry | 6 | 2004 | 11363 | 0.080 |
Why?
|
| Research | 1 | 1997 | 1999 | 0.080 |
Why?
|
| Blast Crisis | 1 | 1989 | 103 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2003 | 2011 | 0.080 |
Why?
|
| Adult | 21 | 2019 | 213712 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2450 | 0.080 |
Why?
|
| Risk Factors | 9 | 2020 | 72145 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2004 | 2049 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 1988 | 4414 | 0.080 |
Why?
|
| Cell Division | 7 | 1997 | 4564 | 0.080 |
Why?
|
| Piperazines | 1 | 2018 | 2488 | 0.080 |
Why?
|
| Collagen | 3 | 1995 | 2684 | 0.080 |
Why?
|
| Receptors, Fibronectin | 2 | 1999 | 39 | 0.080 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 1990 | 433 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 1998 | 1376 | 0.080 |
Why?
|
| Recombinant Proteins | 9 | 1996 | 6608 | 0.080 |
Why?
|
| Kidney | 1 | 2023 | 7167 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 169 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 1996 | 2186 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2003 | 4414 | 0.080 |
Why?
|
| Mass Screening | 1 | 2003 | 5238 | 0.070 |
Why?
|
| Somatomedins | 1 | 2007 | 192 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2011 | 627 | 0.070 |
Why?
|
| Etoposide | 2 | 2000 | 637 | 0.070 |
Why?
|
| Histiocytes | 1 | 1987 | 103 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 640 | 0.070 |
Why?
|
| Health Status | 1 | 2020 | 4030 | 0.070 |
Why?
|
| Carcinosarcoma | 1 | 2007 | 108 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2019 | 3439 | 0.070 |
Why?
|
| Niacinamide | 1 | 2008 | 416 | 0.070 |
Why?
|
| Remission Induction | 2 | 2007 | 2384 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 664 | 0.070 |
Why?
|
| Alprostadil | 1 | 1986 | 89 | 0.070 |
Why?
|
| Fluorouracil | 1 | 2010 | 1615 | 0.070 |
Why?
|
| bcl-X Protein | 2 | 1997 | 411 | 0.070 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 526 | 0.060 |
Why?
|
| Clone Cells | 4 | 1998 | 1692 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 4801 | 0.060 |
Why?
|
| Colony-Forming Units Assay | 1 | 1985 | 354 | 0.060 |
Why?
|
| Immunoblotting | 3 | 1997 | 1683 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 1181 | 0.060 |
Why?
|
| Neutrophils | 4 | 1992 | 3711 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1991 | 821 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 16665 | 0.060 |
Why?
|
| DNA Mutational Analysis | 2 | 2011 | 4187 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 1999 | 2085 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2020 | 23320 | 0.060 |
Why?
|
| Adenocarcinoma | 3 | 2001 | 6347 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2011 | 1780 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2007 | 5062 | 0.060 |
Why?
|
| Receptors, Colony-Stimulating Factor | 4 | 1990 | 49 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2010 | 2215 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2004 | 1484 | 0.060 |
Why?
|
| Genomics | 1 | 2019 | 5692 | 0.060 |
Why?
|
| Climacteric | 1 | 2003 | 57 | 0.060 |
Why?
|
| Mice, Nude | 3 | 1999 | 3689 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2010 | 5522 | 0.060 |
Why?
|
| Sirolimus | 1 | 2010 | 1562 | 0.060 |
Why?
|
| Epithelial Cells | 3 | 2003 | 3678 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2009 | 3913 | 0.060 |
Why?
|
| Quinazolines | 1 | 2009 | 1355 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2000 | 1368 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2005 | 271 | 0.050 |
Why?
|
| Testicular Hormones | 1 | 2003 | 188 | 0.050 |
Why?
|
| Inhibins | 1 | 2003 | 211 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2004 | 279 | 0.050 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 1991 | 110 | 0.050 |
Why?
|
| RNA Interference | 1 | 2011 | 2890 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2007 | 692 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2004 | 660 | 0.050 |
Why?
|
| Back | 1 | 2001 | 66 | 0.050 |
Why?
|
| SEER Program | 1 | 2007 | 1507 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 3504 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1988 | 1835 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 3 | 1999 | 3770 | 0.050 |
Why?
|
| Quality of Life | 2 | 2018 | 12730 | 0.050 |
Why?
|
| Forehead | 1 | 2001 | 69 | 0.050 |
Why?
|
| Philadelphia Chromosome | 2 | 1993 | 112 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 2107 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2011 | 57683 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2003 | 214 | 0.050 |
Why?
|
| RNA, Messenger | 7 | 1998 | 13029 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2003 | 399 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 4029 | 0.050 |
Why?
|
| Recurrence | 1 | 2012 | 8333 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 4 | 1989 | 573 | 0.040 |
Why?
|
| Survival Rate | 2 | 2005 | 12773 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8328 | 0.040 |
Why?
|
| Cell Line | 9 | 1996 | 15994 | 0.040 |
Why?
|
| HLA-DR Antigens | 3 | 1986 | 644 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2011 | 2121 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2001 | 462 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1640 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 430 | 0.040 |
Why?
|
| Lac Operon | 1 | 1999 | 238 | 0.040 |
Why?
|
| Molecular Sequence Data | 5 | 1996 | 18112 | 0.040 |
Why?
|
| T-Lymphocytes | 3 | 1994 | 10163 | 0.040 |
Why?
|
| bcl-Associated Death Protein | 1 | 1998 | 107 | 0.040 |
Why?
|
| Thorax | 1 | 2001 | 547 | 0.040 |
Why?
|
| Interphase | 3 | 1989 | 224 | 0.040 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 1998 | 106 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 184 | 0.040 |
Why?
|
| Ascitic Fluid | 1 | 1998 | 192 | 0.040 |
Why?
|
| Antigens, CD | 3 | 1995 | 4024 | 0.040 |
Why?
|
| Verapamil | 1 | 1998 | 244 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2001 | 6171 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 1999 | 573 | 0.040 |
Why?
|
| Isoantigens | 1 | 2000 | 567 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 2 | 1992 | 849 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2004 | 15056 | 0.040 |
Why?
|
| Patient Participation | 1 | 2007 | 1445 | 0.040 |
Why?
|
| Interleukin-2 | 4 | 1989 | 1887 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 1769 | 0.040 |
Why?
|
| Phosphorylation | 5 | 2001 | 8436 | 0.040 |
Why?
|
| Stem Cells | 2 | 1993 | 3563 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 1999 | 257 | 0.040 |
Why?
|
| Receptors, Immunologic | 3 | 1990 | 1423 | 0.040 |
Why?
|
| Kinetics | 3 | 1996 | 6474 | 0.040 |
Why?
|
| Vinblastine | 1 | 1998 | 490 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12344 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 867 | 0.040 |
Why?
|
| Laparotomy | 1 | 1999 | 474 | 0.040 |
Why?
|
| Laminin | 2 | 1995 | 418 | 0.040 |
Why?
|
| Pyridines | 1 | 2008 | 2818 | 0.040 |
Why?
|
| Neutropenia | 2 | 2000 | 891 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 2000 | 2236 | 0.030 |
Why?
|
| Tyrosine | 2 | 1991 | 1460 | 0.030 |
Why?
|
| G1 Phase | 1 | 1997 | 415 | 0.030 |
Why?
|
| Receptors, Vitronectin | 1 | 1995 | 52 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2001 | 1159 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2001 | 1152 | 0.030 |
Why?
|
| Estradiol | 1 | 2003 | 2021 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1791 | 0.030 |
Why?
|
| Hydroxyurea | 1 | 1996 | 290 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 1995 | 148 | 0.030 |
Why?
|
| Diaphragm | 1 | 1997 | 347 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 559 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1997 | 358 | 0.030 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 2 | 1992 | 48 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1987 | 4455 | 0.030 |
Why?
|
| Endotoxins | 2 | 1988 | 525 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1999 | 1547 | 0.030 |
Why?
|
| Genetic Variation | 2 | 2019 | 6540 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 1996 | 13814 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1997 | 484 | 0.030 |
Why?
|
| Vincristine | 1 | 1996 | 1036 | 0.030 |
Why?
|
| Fibronectins | 2 | 1995 | 723 | 0.030 |
Why?
|
| Leukocyte Count | 4 | 1991 | 1583 | 0.030 |
Why?
|
| Cell Separation | 4 | 1990 | 1749 | 0.030 |
Why?
|
| United States | 3 | 2019 | 69693 | 0.030 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 134 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 1991 | 2455 | 0.030 |
Why?
|
| Hematopoiesis | 3 | 1988 | 2066 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 1996 | 511 | 0.030 |
Why?
|
| Transcription, Genetic | 4 | 1995 | 7721 | 0.030 |
Why?
|
| Cytogenetics | 1 | 1993 | 203 | 0.030 |
Why?
|
| Gene Expression Regulation | 3 | 1987 | 12071 | 0.030 |
Why?
|
| Mice | 7 | 1999 | 81045 | 0.030 |
Why?
|
| Antigens, Surface | 2 | 1988 | 1663 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2001 | 9639 | 0.030 |
Why?
|
| Infusion Pumps | 1 | 1993 | 163 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 1998 | 2382 | 0.030 |
Why?
|
| Binding, Competitive | 2 | 1991 | 1159 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2003 | 2616 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 1171 | 0.030 |
Why?
|
| Cations, Divalent | 1 | 1992 | 166 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1994 | 707 | 0.030 |
Why?
|
| Microbial Collagenase | 1 | 1992 | 122 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1996 | 1099 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 1993 | 230 | 0.020 |
Why?
|
| Tamoxifen | 1 | 1996 | 980 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 2842 | 0.020 |
Why?
|
| Cell Communication | 2 | 1990 | 1619 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 4328 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1994 | 1155 | 0.020 |
Why?
|
| Cell Differentiation | 5 | 1990 | 11470 | 0.020 |
Why?
|
| Models, Genetic | 2 | 2011 | 3493 | 0.020 |
Why?
|
| Decision Making | 1 | 2004 | 3869 | 0.020 |
Why?
|
| Cell Survival | 2 | 1998 | 5872 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 1995 | 1727 | 0.020 |
Why?
|
| Hyaluronic Acid | 1 | 1993 | 489 | 0.020 |
Why?
|
| Cells, Cultured | 6 | 1989 | 19223 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 3 | 1996 | 2505 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 1996 | 1118 | 0.020 |
Why?
|
| S Phase | 1 | 1991 | 423 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1991 | 637 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1999 | 3420 | 0.020 |
Why?
|
| Culture Media | 2 | 1990 | 902 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 14720 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2000 | 2723 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1990 | 351 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 376 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2001 | 12164 | 0.020 |
Why?
|
| DNA Repair | 1 | 1998 | 2042 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 425 | 0.020 |
Why?
|
| Acute Disease | 2 | 1991 | 7141 | 0.020 |
Why?
|
| Animals | 9 | 1999 | 168561 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1994 | 1608 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1996 | 2964 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1990 | 537 | 0.020 |
Why?
|
| Leukopenia | 1 | 1988 | 208 | 0.020 |
Why?
|
| Antibodies | 1 | 1996 | 2459 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2000 | 5519 | 0.020 |
Why?
|
| Blood Cells | 1 | 1990 | 309 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 1995 | 1740 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1999 | 5867 | 0.020 |
Why?
|
| Age Factors | 2 | 2003 | 18355 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 1990 | 694 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1996 | 2968 | 0.020 |
Why?
|
| Palliative Care | 1 | 2002 | 3478 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 1990 | 795 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1991 | 970 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2001 | 12958 | 0.020 |
Why?
|
| Suspensions | 1 | 1986 | 64 | 0.020 |
Why?
|
| Rosette Formation | 1 | 1985 | 153 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1991 | 2271 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 12242 | 0.020 |
Why?
|
| Male | 8 | 2011 | 349538 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1988 | 926 | 0.020 |
Why?
|
| Endocytosis | 1 | 1990 | 983 | 0.020 |
Why?
|
| Disease Progression | 1 | 2001 | 13256 | 0.020 |
Why?
|
| Incidence | 1 | 2003 | 20928 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1990 | 1179 | 0.020 |
Why?
|
| Multigene Family | 1 | 2007 | 1102 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 12797 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 3862 | 0.010 |
Why?
|
| Genes | 1 | 1987 | 1892 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1991 | 1989 | 0.010 |
Why?
|
| Reference Values | 1 | 1990 | 4982 | 0.010 |
Why?
|
| Lymphokines | 1 | 1985 | 949 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1990 | 3001 | 0.010 |
Why?
|
| Protein Binding | 1 | 1994 | 9387 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2007 | 2422 | 0.010 |
Why?
|
| Macrophages | 2 | 1987 | 5655 | 0.010 |
Why?
|
| Vanadates | 2 | 1991 | 82 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1990 | 1515 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2000 | 329 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1999 | 20774 | 0.010 |
Why?
|
| Cell Fusion | 1 | 2000 | 297 | 0.010 |
Why?
|
| Penetrance | 1 | 2001 | 380 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1990 | 1596 | 0.010 |
Why?
|
| Cytokines | 2 | 1991 | 7317 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 678 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 1998 | 200 | 0.010 |
Why?
|
| Genome, Human | 1 | 2011 | 4420 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1997 | 5662 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1987 | 1377 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 40450 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 1097 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2000 | 1341 | 0.010 |
Why?
|
| Histocytological Preparation Techniques | 1 | 1996 | 30 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2000 | 880 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 1999 | 11039 | 0.010 |
Why?
|
| CHO Cells | 1 | 1998 | 1407 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1988 | 4214 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 1866 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 1998 | 853 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1993 | 5425 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2001 | 1144 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2011 | 77098 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 13019 | 0.010 |
Why?
|
| Cricetinae | 1 | 1998 | 2471 | 0.010 |
Why?
|
| Models, Biological | 2 | 2007 | 9581 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 3587 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1993 | 131 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2000 | 1820 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 1998 | 2088 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 19862 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 1998 | 952 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2001 | 2502 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1989 | 7873 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1996 | 1539 | 0.010 |
Why?
|
| Receptors, Interleukin-3 | 1 | 1990 | 30 | 0.010 |
Why?
|
| Thymidine | 1 | 1991 | 309 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 6931 | 0.010 |
Why?
|
| BRCA1 Protein | 1 | 1996 | 1145 | 0.010 |
Why?
|
| Biological Factors | 1 | 1990 | 164 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1991 | 337 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1993 | 664 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1991 | 473 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 2940 | 0.000 |
Why?
|
| Bone Marrow Examination | 1 | 1988 | 157 | 0.000 |
Why?
|
| Erythrocyte Count | 1 | 1988 | 163 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1989 | 829 | 0.000 |
Why?
|
| Methods | 1 | 1988 | 1128 | 0.000 |
Why?
|
| Erythroblasts | 1 | 1988 | 150 | 0.000 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 1998 | 2915 | 0.000 |
Why?
|
| Macrophage-1 Antigen | 1 | 1988 | 290 | 0.000 |
Why?
|
| Blotting, Northern | 1 | 1989 | 1581 | 0.000 |
Why?
|
| Adolescent | 3 | 2009 | 85649 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 1374 | 0.000 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 1801 | 0.000 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 3123 | 0.000 |
Why?
|
| Platelet Count | 1 | 1988 | 780 | 0.000 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1988 | 647 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1989 | 1030 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4229 | 0.000 |
Why?
|
| Epitopes | 1 | 1991 | 2569 | 0.000 |
Why?
|
| DNA Replication | 1 | 1991 | 1397 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 5851 | 0.000 |
Why?
|
| Adjuvants, Immunologic | 1 | 1989 | 1000 | 0.000 |
Why?
|
| Rabbits | 1 | 1990 | 4886 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1988 | 2123 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1991 | 4013 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1993 | 2706 | 0.000 |
Why?
|
| Leukemia | 1 | 1990 | 1507 | 0.000 |
Why?
|
| Lipopolysaccharides | 1 | 1989 | 2211 | 0.000 |
Why?
|
| Lymphoma | 1 | 1990 | 1873 | 0.000 |
Why?
|
| Fever | 1 | 1988 | 1612 | 0.000 |
Why?
|
| Peptides | 1 | 1991 | 4392 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1988 | 6483 | 0.000 |
Why?
|
| Time Factors | 2 | 1990 | 40054 | 0.000 |
Why?
|
| Sarcoma | 1 | 1988 | 1895 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1992 | 5169 | 0.000 |
Why?
|
| Phenotype | 1 | 1990 | 16331 | 0.000 |
Why?
|
| Proteins | 1 | 1986 | 6096 | 0.000 |
Why?
|